Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 9/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | CA9 | Q16790 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6955512 | 0.92 | POLB (0.41) | POLBGAACYP3A4CYP2C9CYP2C19 | |
| SCHEMBL6952131 | 0.92 | POLB (0.41) | POLBGAACYP3A4CYP2C9CYP2C19 | |
| SCHEMBL7615007 | 0.87 | POLB (0.44) | POLBGAACYP3A4CYP2C9CYP2C19 | |
| SCHEMBL6956863 | 0.86 | POLB (0.42) | POLBGAACYP3A4CYP2C9CYP2C19 | |
| SCHEMBL6951261 | 0.86 | POLB (0.42) | POLBGAACYP3A4CYP2C9CYP2C19 | |
| SCHEMBL6952230 | 0.84 | POLB (0.44) | POLBGAACYP3A4CYP2C9CYP2C19 | |
| SCHEMBL6955468 | 0.84 | POLB (0.42) | POLBGAACYP3A4CYP2C9CYP2C19 | |
| SCHEMBL7636167 | 0.84 | POLB (0.47) | POLBGAACYP3A4CYP2C9CYP2C19 | |
| SCHEMBL6957522 | 0.84 | POLB (0.42) | POLBGAACYP3A4CYP2C9CYP2C19 | |
| SCHEMBL6947472 | 0.83 | POLB (0.45) | POLBGAACYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0994890-B1 | BENZIMIDAZOLE DERIVATIVES | GLAXO GROUP LTD (GB) | 2003-08-06 | — | — | EP | disclosed |
| US-6455507-B1 | E.G., 2-BROMO-5,6-DICHLORO-1-BETA-D-RIBOPYRANOSYL-1H-BENZIMIDAZOLE; VIRICIDES, ESPECIALLY INFECTIONS OF HERPES AND CYTOMEGALO VIRUSES | SMITHKLINE BEECHAM CORPORATION | 2002-09-24 | — | — | US | disclosed |
| US-20020094963-A1 | BENZIMIDAZOLE DERIVATIVES | GLAXO WELLCOME INC. | 2002-07-18 | — | — | US | disclosed |
| EP-0994890-A2 | BENZIMIDAZOLE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2000-04-26 | — | — | EP | disclosed |
| WO-1998056761-A2 | BENZIMIDAZOLE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1998-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020094963-A1 | BENZIMIDAZOLE DERIVATIVES | ZC3HAV1, BRPF3, BRD3 | POLB 1342/4885GAA 235/4885CYP3A4 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.